论文部分内容阅读
Raf激酶抑制蛋白(Rafkinase inhibitory protein,RKIP)是磷脂酰乙醇胺结合蛋白(phosphatidylethanolamine-binding protein,PEBP)家族的成员之一,其在丝裂原活化蛋白激酶(mitogen-activated protein kinases,MAPK)、G蛋白偶联受体(G protein-coupled-receptors,GRCP)及核因子-κB(nuclear factor-kappaB,NF-κB)等蛋白激酶信号转导通路中起着重要的调节作用。近年来,在前列腺癌、乳腺癌及黑素瘤等多种恶性肿瘤中均发现RKIP表达下调或缺失,并可能通过抑制细胞侵袭和肿瘤新生血管形成等方式抑制肿瘤转移。同时有多项研究证实,RKIP作为一个肿瘤转移抑制基因,参与抑制了多种消化系统恶性肿瘤的转移,使其成为消化系统肿瘤防治研究的一个新靶点。本文就RKIP在常见消化系统恶性肿瘤中的研究进展作一综述。
Raf kinase inhibitory protein (RKIP) is a member of the phosphatidylethanolamine-binding protein (PEBP) family, which is involved in mitogen-activated protein kinase (MAPK), G G protein-coupled-receptors (GRCP) and nuclear factor-kappaB (NF-κB) and other protein kinase signal transduction pathway plays an important regulatory role. In recent years, the expression of RKIP has been found to be down-regulated or absent in many malignant tumors, such as prostate cancer, breast cancer and melanoma, and the tumor metastasis may be inhibited by inhibiting cell invasion and tumor angiogenesis. At the same time, a number of studies have confirmed that RKIP, as a tumor metastasis suppressor gene, is involved in inhibiting the metastasis of many digestive system malignancies, making it a new target for research on the prevention and treatment of digestive system tumors. This article reviews the research progress of RKIP in common malignant tumors of digestive system.